Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0007095 (
carcinoid
)
6,990
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We analyzed promoter methylation of
RASSF1A
, CTNNB1, CDH1, LAMB3, LAMC2, RUNX3, NORE1A, and CAV1 using methylation-specific PCR in 33 cases of small bowel
carcinoid
with both matched primary and metastatic tumors. The methylation status of
RASSF1A
and CTNNB1 were also determined in six primary appendiceal
carcinoid
tumors. Two neuroendocrine cell lines, NCI-H727 and HTB-119, were analyzed for promoter methylation. Immunohistochemical analyses for
RASSF1A
and beta-catenin were performed in 28 matched primary and metastatic tumors. Western blot analysis for
RASSF1A
and beta-catenin was also performed. Normal enterochromaffin cells were unmethylated in all eight genes examined.
RASSF1A
and CTNNB1 were unmethylated in appendiceal carcinoids. Methylation of
RASSF1A
and CTNNB1 promoters was more frequent in metastatic compared to primary tumors (p = 0.013 and 0.004, respectively). The NCI-H727 and HTB-119 cells lines were methylated in the
RASSF1A
promoter region, and after treatment with 5-aza-2'-deoxycytidine (5-AZA),
RASSF1A
mRNA was expressed in both cell lines. Western blot results for
RASSF1A
and beta-catenin supported the methylation-specific PCR findings. The other six genes did not show significant differences. These results suggest that increased methylation of
RASSF1A
and CTNNB1 may play important roles in progression and metastasis of small bowel
carcinoid
tumors.
...
PMID:Association of DNA methylation and epigenetic inactivation of RASSF1A and beta-catenin with metastasis in small bowel carcinoid tumors. 1752 42
